Pb2118 the Effect of Whole-Body Mri Data on PFS in Patients With Mm in Strict Complete Remission After Auto-HSCT

Abstract

transplant-ineligible patients). Study results indicate that lenalidomide (Rd, VRd) has become the foundation first-line treatment for myeloma in Norway, and the preferred second line if R was not used upfront. The relapse after Rd therapy is managed using bortezomib-based therapies and use of the molecules registered in relapsed or refractory disease including pomalidomide, carfilzomib and daratumumab.